Changchun High & New: Subsidiary's GenSci148 Injection IND Application Accepted

CHANGCHUN HIGH-TECHOn July 8, the Company announced that its subsidiary, GenSci, had received the "Notice of Acceptance" approved and issued by the National Medical Products Administration (NMPA), indicating that the application for clinical trials for the domestic production registration of GenSci148 Injection has been accepted. This drug is a self-developed multi-target VEGF inhibitor intended for the treatment of retinal vascular diseases such as neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.